Spoken Alpha
JOHNSON & JOHNSON
Johnson & Johnson manufactures and sells pharmaceutical medicines and medical devices for treating cancer, immunological disorders, neurological conditions, infectious diseases, cardiovascular disease, and other health conditions, as well as surgical instruments, orthopedic products, and vision care products to hospitals, physicians, healthcare professionals, and consumers worldwide.
JOHNSON & JOHNSON is a Healthcare company operating in Drug Manufacturers - General with a $634.91B market cap.
Most recent reported earnings: Q3 FY2026 (Oct 12, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for JNJ.
$ curl https://api.spokenalpha.com/v1/companies/JNJFAQ
Spoken Alpha indexes JNJ's earnings call transcripts at https://spokenalpha.com/companies/JNJ. Each call links to attributed speakers and parsed analyst Q&A. JOHNSON & JOHNSON's own investor relations page is at https://www.investor.jnj.com/overview/default.aspx.
JOHNSON & JOHNSON (JNJ) held its most recent earnings call on 2026-07-15, covering fiscal Q2 2026.
JOHNSON & JOHNSON (JNJ) operates in the Healthcare sector (Drug Manufacturers - General industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-12 | — | $2.95 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-14 | $2.90 | $2.84 | +2.1% | $25.31B | — | — | EODHD |
| Q1 FY2026 | 2026-04-13 | $2.70 | $2.68 | +0.8% | $24.06B | — | — | EODHD |
| Q4 FY2025 | 2026-01-20 | $2.46 | $2.46 | 0.0% | $24.56B | — | — | EODHD |
| Q3 FY2025 | 2025-10-13 | $2.80 | $2.76 | +1.5% | $23.99B | — | — | EODHD |
| Q2 FY2025 | 2025-07-15 | $2.77 | $2.68 | +3.4% | $23.74B | — | — | EODHD |
| Q1 FY2025 | 2025-04-14 | $2.77 | $2.58 | +7.4% | $21.89B | — | — | EODHD |
| Q4 FY2024 | 2025-01-21 | $2.04 | $2.01 | +1.5% | $22.52B | — | — | EODHD |
| Q3 FY2024 | 2024-10-14 | $2.42 | $2.21 | +9.5% | $22.47B | — | — | EODHD |
| Q2 FY2024 | 2024-07-16 | $2.82 | $2.70 | +4.4% | $22.45B | — | — | EODHD |
| Q1 FY2024 | 2024-04-15 | $2.71 | $2.65 | +2.3% | $21.38B | — | — | EODHD |
| Q4 FY2023 | 2024-01-22 | $2.29 | $2.28 | +0.4% | $21.39B | — | — | EODHD |
| Q3 FY2023 | 2023-10-16 | $2.66 | $2.52 | +5.6% | $21.35B | — | — | EODHD |
| Q2 FY2023 | 2023-07-19 | $2.80 | $2.62 | +6.9% | $21.52B | — | — | EODHD |
| Q1 FY2023 | 2023-04-17 | $2.68 | $2.50 | +7.2% | $20.89B | — | — | EODHD |
| Q4 FY2022 | 2023-01-23 | $2.35 | $2.24 | +4.9% | $23.71B | — | — | EODHD |
| Q3 FY2022 | 2022-10-17 | $2.55 | $2.49 | +2.4% | $23.79B | — | — | EODHD |
| Q2 FY2022 | 2022-07-18 | $2.59 | $2.55 | +1.6% | $24.02B | — | — | EODHD |
| Q1 FY2022 | 2022-04-18 | $2.67 | $2.57 | +3.9% | $23.43B | — | — | EODHD |
| Q4 FY2021 | 2022-01-24 | $2.13 | $2.12 | +0.5% | $24.80B | — | — | EODHD |
Source: EODHD. JNJ reported actuals as published; sparse fields render as —.